Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifiers of non-small-cell lung cancer survival in both men and women

Carcinogenesis

Volumn 31, Issue 10, 2010, Pages 1778-1786

  Olivo Marston, Susan E ^a,b   Mechanic, Leah E ^a   Mollerup, Steen ^c   Bowman, Elise D ^a   Remaley, Alan T ^d   Forman, Michele R ^e   Skaug, Vidar ^c   Zheng, Yun Ling ^f   Haugen, Aage ^c   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF OCCUPATIONAL HEALTH   (Norway)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR ALPHA;

ADULT; AGED; ALLELE; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CASE CONTROL STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DNA POLYMORPHISM; ESTROGEN BLOOD LEVEL; FEMALE; GENDER; GENE CONTROL; HORMONAL THERAPY; HORMONE SYNTHESIS; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; COHORT STUDIES; CYTOCHROME P-450 CYP1A1; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGESTERONE; PROGNOSIS; RNA, MESSENGER;

EID: 77957786489     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq156     Document Type: Article

References (53)

1. American Cancer Society. (2009) Cancer Facts and Figures 2009.
2. Mathers,C.D. et al. (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med., 3, e442.
3. Mathers,C.D. et al. (2002) Global and regional estimates of cancer mortality and incidence by site: I. Application of regional cancer survival model to estimate cancer mortality distribution by site. BMC Cancer, 2, 36.
4. Lee,Y.T. (1984) Better prognosis of many cancers in female: a phenom-enon not explained by study of steroid receptors. J. Surg. Oncol., 25, 255-262.
5. Ramalingam,S. et al. (1998) Lung cancer in young patients: analysis of a surveillance, epidemiology, and end results database. J. Clin. Oncol., 16, 651-657.
6. Stabile,L.P. et al. (2002) Human non-small cell lung tumors and cells de-rived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res., 62, 2141-2150.
7. Weinberg,O.K. et al. (2005) Aromatase inhibitors in human lung cancer therapy. Cancer Res., 65, 11287-11291.
8. Pietras,R.J. et al. (2005) Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids, 70, 372-381.
9. Marquez-Garban,D.C. et al. (2009) Targeting aromatase and estrogen sig-naling in human non-small cell lung cancer. Ann. N. Y. Acad. Sci., 1155, 194-205.
10. Mah,V. et al. (2007) Aromatase expression predicts survival in women with early-stage non small cell lung cancer. Cancer Res., 67, 10484-10490.
11. Mollerup,S. et al. (2002) Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer, 37, 153-159.
12. Canver,C.C. et al. (1994) Sex hormone receptors in non-small-cell lung cancer in human beings. J. Thorac. Cardiovasc. Surg., 108, 153-157.
13. Kawai,H. et al. (2005) Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin. Cancer Res., 11, 5084-5089.
14. Fasco,M.J. et al. (2002) Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue. Mol. Cell. Endocrinol., 188, 125-140.
15. Di,N.L. et al. (2000) Estrogen and progesterone receptors in non-small cell lung cancer in 248 consecutive patients who underwent surgical resection. Arch. Pathol. Lab. Med., 124, 1467-1470.
16. Schwartz,A.G. et al. (2005) Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin. Cancer Res., 11, 7280-7287.
17. Radzikowska,E. et al. (2002) Estrogen and progesterone receptors in non small cell lung cancer patients. Ann. Thorac. Cardiovasc. Surg., 8, 69-73.
18. Ivanova,M.M. et al. (2009) Activity and intracellular location of estrogen receptors alpha and beta in human bronchial epithelial cells. Mol. Cell. Endocrinol., 305, 12-21.
19. Ali,G. et al. (2008) Different estrogen receptor beta expression in distinct histologic subtypes of lung adenocarcinoma. Hum. Pathol., 39, 1465-1473.
20. Pearce,S.T. et al. (2004) The biological role of estrogen receptors alpha and beta in cancer. Crit. Rev. Oncol. Hematol., 50, 3-22.
21. Suzuki,T. et al. (2003) Intracrine mechanism of estrogen synthesis in breast cancer. Biomed. Pharmacother., 57, 460-462.
22. Olson,S.H. et al. (2007) Variants in estrogen biosynthesis genes, sex steroid hormone levels, and endometrial cancer: a HuGE review. Am. J. Epidemiol., 165, 235-245.
23. Mason,J.I. et al. (1997) The regulation of 3 beta-hydroxysteroid dehydrogenase expression. Steroids, 62, 164-168.
24. Jefcoate,C.R. et al. (2000) Tissue-specific synthesis and oxidative metabolism of estrogens. J. Natl Cancer Inst. Monogr., 27, 95-112.
25. Mechanic,L.E. et al. (2005) Polymorphisms in XPD and TP53 and mutation in human lung cancer. Carcinogenesis, 26, 597-604.
26. Zheng,Y.L. et al. (2003) Bleomycin-induced chromosome breaks as a risk marker for lung cancer: a case-control study with population and hospital controls. Carcinogenesis, 24, 269-274.
27. Lababede,O. et al. (1999) TNM staging of lung cancer: a quick reference chart. Chest, 115, 233-235.
28. StataCorp. (2005) Stata Statistical Software: Release 9. StataCorp LP, College Station, TX.
29. Gardner,D. et al. (2007) Greenspan's Basic & Clinical Endocrinology: Eighth Edition, 8th edn. McGraw-Hill Medical, New York, NY.
30. Kerr,A. et al. (2008) Steroid receptor and growth factor receptor expression in human nonsmall cell lung cancers using cells procured by laser-capture microdissection. Adv. Exp. Med. Biol., 617, 377-384.
31. Brown,L.A. et al. (2008) ESR1 gene amplification in breast cancer: a common phenomenon? Nat. Genet., 40, 806-807.
32. Horlings,H.M. et al. (2008) ESR1 gene amplification in breast cancer: a common phenomenon? Nat. Genet., 40, 807-808.
33. Holst,F. et al. (2007) Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat. Genet., 39, 655-660.
34. Baron,J.A. (1996) Beneficial effects of nicotine and cigarette smoking: the real, the possible and the spurious. Br. Med. Bull., 52, 58-73.
35. Taioli,E. et al. (1994) Re: endocrine factors and adenocarcinoma of the lung in women. J. Natl Cancer Inst., 86, 869-870.
36. Moore,K.A. et al. (2003) Menopausal effects on presentation, treatment, and survival of women with non-small cell lung cancer. Ann. Thorac. Surg., 76, 1789-1795.
37. Brenner,A.V. et al. (2003) Menstrual and reproductive factors and risk of lung cancer among Chinese women, Eastern Gansu Province, 1994-1998. J. Epidemiol., 13, 22-28.
38. Liao,M.L. et al. (1996) A study of the association between squamous cell carcinoma and adenocarcinoma in the lung, and history of menstruation in Shanghai women, China. Lung Cancer, 14 (suppl. 1), S215-S221.
39. Seow,A. et al. (2002) Diet, reproductive factors and lung cancer risk among Chinese women in Singapore: evidence for a protective effect of soy in nonsmokers. Int. J. Cancer, 97, 365-371.
40. Schwartz,A.G. et al. (2007) Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J. Clin. Oncol., 25, 5785-5792.
41. Adami,H.O. et al. (1989) Risk of cancer in women receiving hormone replacement therapy. Int. J. Cancer, 44, 833-839.
42. Ganti,A.K. et al. (2006) Hormone replacement therapy is associated with decreased survival in women with lung cancer. J. Clin. Oncol., 24, 59-63.
43. Wu,A.H. et al. (1988) Personal and family history of lung disease as risk factors for adenocarcinoma of the lung. Cancer Res., 48, 7279-7284.
44. Elliott,A.M. et al. (2006) Use of exogenous hormones by women and lung cancer: evidence from the Royal College of General Practitioners' Oral Contraception Study. Contraception, 73, 331-335.
45. Kabat,G.C. et al. (2007) Reproductive and hormonal factors and risk of lung cancer in women: a prospective cohort study. Int. J. Cancer, 120, 2214-2220.
46. Chlebowski,R.T. et al. (2009) Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet, 374, 1243-1251.
47. Slatore,C.G. et al. (2010) Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. J. Clin. Oncol., 28, 1540-1546.
48. Peters,G.A. et al. (1999) Estrogen receptor domains E and F: role in dimerization and interaction with coactivator RIP-140. Mol. Endocrinol., 13, 286-296.
49. Nilsson,S. et al. (2000) Estrogen receptor transcription and transactivation: basic aspects of estrogen action. Breast Cancer Res., 2, 360-366.
50. Montano,M.M. et al. (1995) The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Mol. Endocrinol., 9, 814-825.
51. Hart,L.L. et al. (2002) The estrogen receptor: more than the average transcription factor. Biochem. Cell Biol., 80, 335-341.
52. Graham,J.D. et al. (1997) Physiological action of progesterone in target tissues. Endocr. Rev., 18, 502-519.
53. Dunning,A.M. et al. (2004) Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J. Natl Cancer Inst., 96, 936-945.